These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 15061251)

  • 1. Secretin for refractory schizophrenia.
    Sheitman BB; Knable MB; Jarskog LF; Chakos M; Boyce LH; Early J; Lieberman JA
    Schizophr Res; 2004 Feb; 66(2-3):177-81. PubMed ID: 15061251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study.
    Lightdale JR; Hayer C; Duer A; Lind-White C; Jenkins S; Siegel B; Elliott GR; Heyman MB
    Pediatrics; 2001 Nov; 108(5):E90. PubMed ID: 11694674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism.
    Coniglio SJ; Lewis JD; Lang C; Burns TG; Subhani-Siddique R; Weintraub A; Schub H; Holden EW
    J Pediatr; 2001 May; 138(5):649-55. PubMed ID: 11343038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism.
    Unis AS; Munson JA; Rogers SJ; Goldson E; Osterling J; Gabriels R; Abbott RD; Dawson G
    J Am Acad Child Adolesc Psychiatry; 2002 Nov; 41(11):1315-21. PubMed ID: 12410073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of benefit of intravenous synthetic human secretin in the treatment of autism.
    Molloy CA; Manning-Courtney P; Swayne S; Bean J; Brown JM; Murray DS; Kinsman AM; Brasington M; Ulrich CD
    J Autism Dev Disord; 2002 Dec; 32(6):545-51. PubMed ID: 12553591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial.
    Roberts W; Weaver L; Brian J; Bryson S; Emelianova S; Griffiths AM; MacKinnon B; Yim C; Wolpin J; Koren G
    Pediatrics; 2001 May; 107(5):E71. PubMed ID: 11331721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM; Yang R; Youakim JM
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features.
    Alamy SS; Jarskog LF; Sheitman BB; Lieberman JA
    Schizophr Res; 2004 Feb; 66(2-3):183-6. PubMed ID: 15061252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism.
    Corbett B; Khan K; Czapansky-Beilman D; Brady N; Dropik P; Goldman DZ; Delaney K; Sharp H; Mueller I; Shapiro E; Ziegler R
    Clin Pediatr (Phila); 2001 Jun; 40(6):327-31. PubMed ID: 11824175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
    Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ
    Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homeopathic Secretin in autism: a clinical pilot study.
    Robinson TW
    Br Homeopath J; 2001 Apr; 90(2):86-91. PubMed ID: 11341462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism.
    Owley T; McMahon W; Cook EH; Laulhere T; South M; Mays LZ; Shernoff ES; Lainhart J; Modahl CB; Corsello C; Ozonoff S; Risi S; Lord C; Leventhal BL; Filipek PA
    J Am Acad Child Adolesc Psychiatry; 2001 Nov; 40(11):1293-9. PubMed ID: 11699803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple doses of secretin in the treatment of autism: a controlled study.
    Sponheim E; Oftedal G; Helverschou SB
    Acta Paediatr; 2002; 91(5):540-5. PubMed ID: 12113323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief PANSS to assess and monitor the overall severity of schizophrenia.
    Yamamoto N; Inada T; Shimodera S; Morokuma I; Furukawa TA
    Psychiatry Clin Neurosci; 2010 Jun; 64(3):262-7. PubMed ID: 20602726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia.
    Lee J; Fervaha G; Takeuchi H; Powell V; Remington G
    J Clin Psychopharmacol; 2015 Jun; 35(3):237-41. PubMed ID: 25839337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.